Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 4Tumor-Agnostic 1Other solid neoplasm 1Gynecologic 1Endocrine 1

Conditions

Neoplasm Metastasis 1

Interventions

pembrolizumab 18Nivolumab 18Gemcitabine 9Ipilimumab 8Cisplatin 8Carboplatin 8Capecitabine 8Paclitaxel 6Cetuximab 6atezolizumab 5Irinotecan 5Docetaxel 5Cyclophosphamide 5Bevacizumab 5avelumab 4Trastuzumab 4Fluorouracil 4trametinib 3spartalizumab 3Specimen Handling 3Pemetrexed 3Leucovorin 3Everolimus 3Dexamethasone 3Biopsy 3urelumab 2toripalimab 2tislelizumab 2ribociclib 2repotrectinib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × berzosertib × Tumor-Agnostic × Clear all
NCT04266912 2025-11-25

Avelumab and M6620 for the Treatment of DDR Deficient Metastatic or Unresectable Solid Tumors

M.D. Anderson Cancer Center

Phase 1/2 Active not recruiting
23 enrolled 11 charts
Tumor-Agnostic

Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡